Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery
Harm H H Feringa, Olaf Schouten, Martin Dunkelgrun, Jeroen J Bax, Eric Boersma, Abdou Elhendy, Robert de Jonge, Stefanos E Karagiannis, Radosav Vidakovic, Don Poldermans, Harm H H Feringa, Olaf Schouten, Martin Dunkelgrun, Jeroen J Bax, Eric Boersma, Abdou Elhendy, Robert de Jonge, Stefanos E Karagiannis, Radosav Vidakovic, Don Poldermans
Abstract
Objective: To assess the long-term prognostic value of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) after major vascular surgery.
Design: A single-centre prospective cohort study.
Patients: 335 patients who underwent abdominal aortic aneurysm repair or lower extremity bypass surgery.
Interventions: Prior to surgery, baseline NT-proBNP level was measured. Patients were also evaluated for cardiac risk factors according to the Revised Cardiac Risk Index. Dobutamine stress echocardiography (DSE) was performed to detect stress-induced myocardial ischaemia.
Main outcome measures: The prognostic value of NT-proBNP was evaluated for the endpoints all-cause mortality and major adverse cardiac events (MACE) during long-term follow-up.
Results: In this patient cohort (mean age: 62 years, 76% male), median NT-proBNP level was 186 ng/l (interquartile range: 65-444 ng/l). During a mean follow-up of 14 (SD 6) months, 49 patients (15%) died and 50 (15%) experienced a MACE. Using receiver operating characteristic curve analysis for 6-month mortality and MACE, NT-proBNP had the greatest area under the curve compared with cardiac risk score and DSE. In addition, an NT-proBNP level of 319 ng/l was identified as the optimal cut-off value to predict 6-month mortality and MACE. After adjustment for age, cardiac risk score, DSE results and cardioprotective medication, NT-proBNP > or =319 ng/l was associated with a hazard ratio of 4.0 for all-cause mortality (95% CI: 1.8 to 8.9) and with a hazard ratio of 10.9 for MACE (95% CI: 4.1 to 27.9).
Conclusion: Preoperative NT-proBNP level is a strong predictor of long-term mortality and major adverse cardiac events after major non-cardiac vascular surgery.
Conflict of interest statement
Competing interests: None.
Figures
References
- Eagle K A, Berger P B, Calkins al American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery‐‐executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Non‐cardiac Surgery). Circulation 20021051257–1267.
- Mangano D T, Browner W S, Hollander al Long‐term cardiac prognosis following noncardiac surgery. The Study of Perioperative Ischemia Research Group. JAMA 1992268233–239.
- Poldermans D, Boersma E, Bax J al The effect of bisoprolol on perioperative mortality and myocardial infarction in high‐risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 19993411789–1794.
- Bartels C, Bechtel J F, Hossmann al Cardiac risk stratification for high‐risk vascular surgery. Circulation 1997952473–2475.
- Sprung J, Abdelmalak B, Gottlieb al Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery. Anesthesiology 200093129–140.
- Goldman L, Caldera D L, Nussbaum S al Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977297845–850.
- Detsky A S, Abrams H B, McLaughlin J al Predicting cardiac complications in patients undergoing non‐cardiac surgery. J Gen Intern Med 19861211–219.
- Lee T H, Marcantonio E R, Mangione C al Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation 19991001043–1049.
- Kertai M D, Boersma E, Klein al Optimizing the prediction of perioperative mortality in vascular surgery by using a customized probability model. Arch Intern Med 2005165898–904.
- Boersma E, Poldermans D, Bax J al DECREASE Study Group (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography). Predictors of cardiac events after major vascular surgery: role of clinical characteristics, dobutamine echocardiography, and beta‐blocker therapy, JAMA 20012851865–1873.
- Levin E R, Gardner D G, Samson W K. Natriuretic peptides. N Engl J Med 1998339321–328.
- Hall C. Essential biochemistry and physiology of (NT‐pro)BNP. Eur J Heart Fail 20046257–260.
- Yoshimura M, Yasue H, Okumura al Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 199387464–469.
- Yasue H, Yoshimura M, Sumida al Localization and mechanism of secretion of B‐type natriuretic peptide in comparison with those of A‐type natriuretic peptide in normal subjects and patients with heart failure. Circulation 199490195–203.
- Lainchbury J G, Campbell E, Frampton C al Brain natriuretic peptide and n‐terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 200342728–735.
- Bettencourt P, Azevedo A, Pimenta al N‐terminal‐pro‐brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 20041102168–2174.
- Schnabel R, Rupprecht H J, Lackner K al AtheroGene Investigators. Analysis of N‐terminal‐pro‐brain natriuretic peptide and C‐reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study, Eur Heart J 200526241–249.
- Kragelund C, Gronning B, Kober al N‐terminal pro‐B‐type natriuretic peptide and long‐term mortality in stable coronary heart disease. N Engl J Med 2005352666–675.
- Yeh H M, Lau H P, Lin J al Preoperative plasma N‐terminal pro‐brain natriuretic peptide as a marker of cardiac risk in patients undergoing elective non‐cardiac surgery. Br J Surg 2005921041–1045.
- Richards A M, Doughty R, Nicholls M al Australia‐New Zealand Heart Failure Group. Plasma N‐terminal pro‐brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction, Australia‐New Zealand Heart Failure Group. J Am Coll Cardiol 2001371781–1787.
- Gardner R S, Ozalp F, Murday A al N‐terminal pro‐brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003241735–1743.
- James S K, Lindahl B, Siegbahn al N‐terminal pro‐brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV substudy. Circulation 2003108275–281.
- Omland T, Persson A, Ng al N‐terminal pro‐B‐type natriuretic peptide and long‐term mortality in acute coronary syndromes. Circulation 20021062913–2918.
- Jernberg T, Stridsberg M, Venge al N‐terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST‐segment elevation. J Am Coll Cardiol 200240437–445.
- Poldermans D, Bax J J, Kertai M al Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. Circulation 20031071848–1851.
- Eagle K A, Rihal C S, Mickel M al Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations. CASS Investigators and University of Michigan Heart Care Program. Coronary Artery Surgery Study. Circulation 1997961882–1887.
- McFalls E O, Ward H B, Moritz T al Coronary artery revascularization before elective major vascular surgery. N Engl J Med 20043512795–2804.
Source: PubMed